Recipients of a Liver Transplant or Victims of Liver Disease at Risk for NSF
According to the FDA, patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing the debilitating, and a potentially fatal disease, Nephrogenic Systemic Fibrosis (NSF). Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents. In addition, patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity. FDA first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006.
Continue reading "Recipients of a Liver Transplant or Victims of Liver Disease at Risk for NSF" »
